Patents by Inventor Tsukasa Seya
Tsukasa Seya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230210925Abstract: A composition for activating cytotoxic T lymphocytes (CTLs) containing a spirulina extract is provided. A composition for CTL activation for proliferation of cytotoxic T lymphocytes (CTLs) containing a spirulina extract is provided. Moreover, a pharmaceutical composition for CTL activation or a food or a drink for CTL activation containing the composition for CTL activation is provided.Type: ApplicationFiled: July 9, 2021Publication date: July 6, 2023Applicants: DIC Corporation, National University Corporation Hokkaido UniversityInventors: Yasuyuki Imai, Tomohiro Hirahashi, Masanori Kasahara, Aya Miyazaki, Tsukasa Seya, Misako Matsumoto, Utano Tomaru
-
Patent number: 11065331Abstract: The present invention relates to a medicament for treating cancer or infectious disease, the medicament comprising an immune checkpoint blockade and an adjuvant composition. More specifically, the present invention relates to a medicament for cancer or infectious diseases, wherein an anti-PD-1 antibody or an anti-PD-L1 antibody is used in combination with a nucleic acid adjuvant composed of a double-stranded RNA and a single-stranded ODN.Type: GrantFiled: July 26, 2017Date of Patent: July 20, 2021Assignee: Advanced Innovation Development Co. Ltd.Inventors: Tsukasa Seya, Misako Matsumoto
-
Publication number: 20190160168Abstract: The present invention relates to a medicament for treating cancer or infectious disease, the medicament comprising an immune checkpoint blockade and an adjuvant composition. More specifically, the present invention relates to a medicament for cancer or infectious diseases, wherein an anti-PD-1 antibody or an anti-PD-L1 antibody is used in combination with a nucleic acid adjuvant composed of a double-stranded RNA and a single-stranded ODN.Type: ApplicationFiled: July 26, 2017Publication date: May 30, 2019Applicant: Advanced Innovation Development Co. Ltd.Inventors: Tsukasa SEYA, Misako MATSUMOTO
-
Patent number: 10105385Abstract: Provided is an adjuvant composition comprising a nucleic acid comprising a double-stranded RNA bound to a single-stranded DNA, the double-stranded RNA consisting of a nucleotide sequence of SEQ ID NO: 1 and its complementary sequence, the single-stranded DNA consisting of a nucleotide sequence of SEQ ID NO: 2. Also provided is a vaccine composition comprising the adjuvant composition and an antigen or an antigen component. The nucleic acid contained in the adjuvant composition is a chemically synthesizable nucleic acid having potent adjuvant activity and high safety.Type: GrantFiled: December 1, 2015Date of Patent: October 23, 2018Assignee: National University Corporation Hokkaido UniversityInventors: Tsukasa Seya, Misako Matsumoto
-
Publication number: 20180280425Abstract: Provided is an adjuvant composition comprising a nucleic acid comprising a double-stranded RNA bound to a single-stranded DNA, the double-stranded RNA consisting of a nucleotide sequence of SEQ ID NO: 1 and its complementary sequence, the single-stranded DNA consisting of a nucleotide sequence of SEQ ID NO: 2. Also provided is a vaccine composition comprising the adjuvant composition and an antigen or an antigen component. The nucleic acid contained in the adjuvant composition is a chemically synthesizable nucleic acid having potent adjuvant activity and high safety.Type: ApplicationFiled: December 1, 2015Publication date: October 4, 2018Inventors: Tsukasa Seya, Misako Matsumoto
-
Patent number: 9090650Abstract: The disclosed nucleic acid at least containing a single-stranded DNA to be delivered to endosomes of dendritic cells and a double-stranded RNA capable of activating TLR3 can be delivered to endosomal TLR3 and has a strong adjuvanticity with few side effects, and therefore is useful as an active ingredient of immunostimulants, vaccine adjuvants, cancer therapeutic agents and the like.Type: GrantFiled: July 27, 2011Date of Patent: July 28, 2015Assignee: National University Corporation Hokkaido UniversityInventors: Tsukasa Seya, Misako Matsumoto
-
Publication number: 20130178611Abstract: The disclosed nucleic acid at least containing a single-stranded DNA to be delivered to endosomes of dendritic cells and a double-stranded RNA capable of activating TLR3 can be delivered to endosomal TLR3 and has a strong adjuvanticity with few side effects, and therefore is useful as an active ingredient of immunostimulants, vaccine adjuvants, cancer therapeutic agents and the like.Type: ApplicationFiled: July 27, 2011Publication date: July 11, 2013Applicant: National University Corporation Hokkaido UniversityInventors: Tsukasa Seya, Misako Matsumoto
-
Patent number: 8076460Abstract: The present invention provides a monoclonal antibody which specifically binds to human Toll-like receptor 3 and inhibits production of type 1 interferon. It also provides an inhibitor which (a) suppresses a double-stranded RNA-mediated immune response in a cell which expresses Toll-like receptor 3 that recognizes the double-stranded RNA and produces type I interferon, and (b) includes an antibody, which binds to the Toll-like receptor 3 and inhibits production of the type I interferon. Particularly, the monoclonal antibody is against human Toll-like receptor 3. Further, a transfection method and kit are provided. Production of type I interferon can be controlled by using an antibody which specifically binds to Toll-like receptor 3 that recognizes a double-stranded RNA and produces type I interferon.Type: GrantFiled: December 12, 2008Date of Patent: December 13, 2011Assignee: Japan Science and Technology AgencyInventors: Misako Matsumoto, Tsukasa Seya
-
Patent number: 8029778Abstract: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or 4, specifically binds to the mammalian Toll-like receptor 3 and induces production of type I interferon. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4). The gene is a gene encoding the adaptor protein TICAM-1.Type: GrantFiled: March 31, 2009Date of Patent: October 4, 2011Assignee: Japan Science and Technology AgencyInventors: Tsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
-
Patent number: 8021879Abstract: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or 4, specifically binds to the mammalian Toll-like receptor 3 and induces production of type I interferon. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4). The gene is a gene encoding the adaptor protein TICAM-1.Type: GrantFiled: March 31, 2009Date of Patent: September 20, 2011Assignee: Japan Science and Technology AgencyInventors: Tsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
-
Publication number: 20100087510Abstract: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or 4, specifically binds to the mammalian Toll-like receptor 3 and induces production of type I interferon. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4). The gene is a gene encoding the adaptor protein TICAM-1.Type: ApplicationFiled: March 31, 2009Publication date: April 8, 2010Applicant: Japan Science and Technology AgencyInventors: Tsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
-
Publication number: 20090275644Abstract: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or 4, specifically binds to the mammalian Toll-like receptor 3 and induces production of type I interferon. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4). The gene is a gene encoding the adaptor protein TICAM-1.Type: ApplicationFiled: March 31, 2009Publication date: November 5, 2009Applicant: Japan Science and Technology AgencyInventors: Tsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
-
Patent number: 7582437Abstract: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or NO: 4, has the property of specifically binding to the mammalian Toll-like receptor 3 and a property of inducing type I interferon production. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4. The gene is a gene encoding the adaptor protein TICAM-1.Type: GrantFiled: November 20, 2003Date of Patent: September 1, 2009Assignee: Japan Science and Technology AgencyInventors: Tsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
-
Publication number: 20090105460Abstract: The present invention provides a monoclonal antibody which specifically binds to human Toll-like receptor 3 and inhibits production of type 1 interferon. It also provides an inhibitor which (a) suppresses a double-stranded RNA-mediated immune response in a cell which expresses Toll-like receptor 3 that recognizes the double-stranded RNA and produces type I interferon, and (b) includes an antibody, which binds to the Toll-like receptor 3 and inhibits production of the type I interferon. Particularly, the monoclonal antibody is against human Toll-like receptor 3. Further, a transfection method and kit are provided. Production of type I interferon can be controlled by using an antibody which specifically binds to Toll-like receptor 3 that recognizes a double-stranded RNA and produces type I interferon.Type: ApplicationFiled: December 12, 2008Publication date: April 23, 2009Applicant: Japan Science and Technology AgencyInventors: Misako Matsumoto, Tsukasa Seya
-
Publication number: 20060134128Abstract: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or NO: 4, has the property of specifically binding to the mammalian Toll-like receptor 3 and a property of inducing type I interferon production. A mutant of the adaptor protein TICAM- 1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4. The gene is a gene encoding the adaptor protein TICAM-1.Type: ApplicationFiled: November 20, 2003Publication date: June 22, 2006Inventors: Tsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
-
Publication number: 20050153910Abstract: The present invention provides a monoclonal antibody which specifically binds to human Toll-like receptor 3. Further, the present invention provides an inhibitor which (a) suppresses a double-stranded RNA-mediated immune response in a cell which expresses Toll-like receptor recognizing the double-stranded RNA and produces type I interferon, and (b) includes an antibody, which binds to the Toll-like receptor and inhibits production of the type I interferon. Particularly, the antibody is a monoclonal antibody against human Toll-like receptor 3.Type: ApplicationFiled: February 17, 2003Publication date: July 14, 2005Inventors: Misako Matsumoto, Tsukasa Seya
-
Publication number: 20050096272Abstract: The present invention is to provide cytokine inducers comprising a membrane protein M161Ag which is contained in cells latently infected with Mycoplasma fermentans such as a human myelocytic leukemia cell line P39(+). The present invention relates to cytokine inducers comprising the protein M161Ag or gene recombinant products thereof which are useful for immunomodulators, or therapeutic agents for various immune related diseases and solid tumors.Type: ApplicationFiled: August 5, 2004Publication date: May 5, 2005Inventors: Tsukasa Seya, Misako Matsumoto
-
Publication number: 20030108527Abstract: This invention relates to dendritic cells that are matured by utilizing a cell wall skeleton of a Gram positive bacteria-CWS and a process for maturing said cells, as well as a composition for accelerating the maturation of immature dendritic cells comprising a Gram positive bacteria-CWS as an essential component.Type: ApplicationFiled: October 29, 2002Publication date: June 12, 2003Inventors: Tsukasa Seya, Shoutaro Tsuji, Misako Matsumoto, Akira Hayashi, Ichiro Azuma